Nerviano Medical Sciences Appointed Paramjit Kaur, PhD to Accelerate PERK/GCN2 Inhibitor Asset Development
NERVIANO, May 17th 2023 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Paramjit Kaur,...
Nerviano Medical Sciences S.r.l. to Present at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Nerviano Medical Sciences S.r.l. to Present at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting NMS-153: A clinical-phase, potent and highly selective small molecule inhibitor of Monopolar Spindle 1 with differentiated mechanism of...
1st European Cancer Dependency Map Symposium successfully concluded in Milan on May 9th, sponsored by Nerviano Medical Sciences Srl
Nerviano 9 May 2023_ Nerviano Medical Sciences Srl (NMS) was delighted to be the title sponsor of the 1st European Cancer Dependency Map Symposium, together with Astra Zeneca. This is an international event organized by scientists at Human Technopole, EMBL – European...
Nerviano Medical Sciences included as AACR 2023 Plenary Session highlights for its NMS-03592088 Phase 1 Clinical Trial Data in Patients with FLT3 positive Relapsed or Refractory Acute Myeloid Leukemia
Nerviano 21 April 2023_Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to be included as Plenary Session highlights of the AACR (American...
Welcome and Check out our new motion picture!
Recent Comments